Key result
Postprocedural cardiac troponin I increase after elective PCI was significantly predictive of adverse events at 18 months (OR 18.9; 95% CI 9.7-37; p<0.0001).
Why the study?
Does postprocedural cardiac troponin I increase predict major adverse cardiac events in patients with stable coronary disease undergoing elective PCI?
Cohort (n=316)
Does postprocedural cardiac troponin I increase predict major adverse cardiac events in patients with stable coronary disease undergoing elective PCI?
Odds Ratio: 18.9 (95% CI 9.7–37)
p-value: p=<0.0001
Postprocedural cTnI elevation after elective PCI in stable coronary disease is a strong independent predictor of adverse events at 18 months, primarily driven by repeat revascularization.
No takes yet. Share an insight, caveat, or question.
May warrant enhanced post-PCI surveillance in stable CAD; leaves open whether troponin-guided interventions improve outcomes.
Thuraia Nageh (2005) conducted a cohort in Stable coronary disease undergoing percutaneous coronary intervention (n=316). Postprocedural cardiac troponin I (cTnI) increase vs. No postprocedural cTnI increase was evaluated on Major adverse cardiac events (MACE) at 30 days and at 18 months after PCI: death, Q wave myocardial infarction (MI), or repeat revascularisation in hospital (OR 18.9, 95% CI 9.7-37, p=<0.0001). Postprocedural cardiac troponin I increase after elective PCI was significantly predictive of adverse events at 18 months (OR 18.9; 95% CI 9.7-37; p<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: